The Centers for Medicare and Medicaid Services (CMS) announced on Friday it has revised its guidance for the Medicare drug price negotiation program set up within the Inflation Reduction Act (IRA), seemingly in response to the several lawsuits challenging the program's constitutionality. Negotiations under the Medicare Drug Price Negotiation Program are set to take place over course of 2023 and 2024. Before those talks could get very far, several organizations filed lawsuits seeking to block the program and void any agreements that might be reached. Merck, Bristol Myers Squibb, the Chamber of Commerce and the pharmaceutical trade group PhRMA have all filed lawsuits against the Biden a
Hence then, the article about biden admin revises drug negotiation program amid legal onslaught was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Biden admin revises drug negotiation program amid legal onslaught )